Cochlear Limited

About: Cochlear Limited is a company organization based out in Sydney, New South Wales, Australia. It is known for research contribution in the topics: Cochlear implant & Hearing loss. The organization has 1290 authors who have published 1479 publications receiving 33109 citations. The organization is also known as: кохлеарные Americas & COCHLEAR LIMITED.

Bimodal speech processor

Abstract: A bimodal aid comprising a speech processor (11) linked to an acoustic aid processor (12). Both processors derive audible information, particularly speech information, from a microphone (13). The speech processor processes the audio information according to patient-specific settings stored in a memory (23) in order to apply a control signal to an implant aid (15) in one ear of a patient. The acoustic aid signal processor (12) further processes information derived from and by the speech processor (11) in accordance with patient-specific settings in memory (23) so as to supply a control signal to an acoustic aid (14) located in the other ear of the patient. The acoustic aid signal processor (12) incorporates a programmable filter device which allows for rapid, iterative adaptation of the bimodal aid to the subjective auditory requirements of the patient. The bimodal aid can be used to drive an implant aid (15) only or to drive an acoustic aid (14) only.

Cochlear implant assembly

Abstract: A method of forming and connecting an antenna to a feedthrough member of a housing, The method comprising a step of: positioning the feedthrough member and an antenna template relative to each other. A step of connecting the first portion of at least one electrically conducting wire to the feedthrough member. An additional step of winding the wire at least once around the antenna template, and a further step of connecting a second portion of each wire to said feedthrough member.

Prevalence of cochlear imPlants in euroPe: What do We knoW and What can We exPect?

Abstract: Results: The degree of utilisation of cochlear implantation by suitable children and adults varies considerably between the European countries. Most less affluent East European countries focus on the implantation of children rather than adults. Although adult recipient numbers are growing, it has been estimated that less than 10% of adult candidates in Europe receive a CI. There is little to no scientific data available on late onset, or progressive, hearing loss in children or adults.

A mouse model of cochlear implantation with chronic electric stimulation.

Abstract: Objectives Cochlear implants provide an effective treatment option for those with severe hearing loss, including those with preserved low frequency hearing. However, certain issues can reduce implant efficacy including intracochlear tissue response and delayed loss of residual acoustic hearing. We describe a mouse model of cochlear implantation with chronic electric stimulation that can be used to study cochlear implant biology and related pathologies. Methods Twelve normal hearing adult CBA/J mice underwent unilateral cochlear implantation and were evenly divided into one group receiving electric stimulation and one not. Serial impedance and neural response telemetry (NRT) measurements were made to assess implant functionality. Functionality was defined as having at least one electrode with an impedance ≤ 35 kOhms. Mouse cochleae were harvested for histology and 3D x-ray microscopy 21 days post-operatively, or, in case the implant was still functional, at a later time point when the implant failed. A separate experiment measured the hearing preservation rate in 7 adult CBA/J mice undergoing unilateral cochlear implantation with serial auditory brainstem response (ABR) and distortion product otoacoustic emissions (DPOAE). Results Implants maintained functionality for a mean of 35 days in the non-stimulated group and 19.8 days in the stimulated group. Reliable NRT and behavioral responses to electric stimulation were recorded. A robust intracochlear peri-implant tissue response with neo-ossification was seen in all cochleae. Six of seven mice maintained intact low frequency hearing up to 6 weeks following cochlear implantation. Conclusions We demonstrate the feasibility of cochlear implantation and behaviorally significant electric stimulation in the mouse, with the potential for hearing preservation. This model may be combined with established mouse models of hearing loss and the large genetic and molecular research toolkit unique to the mouse for mechanistic and therapeutic investigations of cochlear implant biology.

Pediatric outcomes with the nucleus 24 contour: North American clinical trial.

Abstract: The Nucleus 24 Contour is a new cochlear implant that has recently undergone clinical trials in adults and children. The Contour uses the same electronics as the previous-generation Nucleus 24 (CI24M) but incorporates a downsized receiver-stimulator and a perimodiolar electrode array. The indications for use were expanded to include children as young as 12 months of age and children 24 months of age and older with severe to profound hearing loss who had open-set word recognition up to 30%. The Contour was successfully implanted in 256 children. The mean level of postoperative speech perception with the Contour was significantly better than the preoperative baseline with hearing aids on all measures. Children who had open-set speech perception in an audition-only condition before surgery demonstrated higher levels of postoperative performance with the Contour than children with no open-set speech perception before surgery.